KIT was initially thought to act as a tumor suppressor gene, because its presence in normal melanocytes and benign nevi, and its loss during progression and in metastatic melanoma was reported (Montone et al., 1997; Shen et al., 2003; Isabel Zhu and Fitzpatrick, 2006). This evidence concerns the gene KIT and metastatic melanoma.